Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB4 known ✓ | P30926 | 1/20 | 0.33 |
| ▸ | CHRNA3 known ✓ | P32297 | 1/20 | 0.33 |
| ▸ | CHRNA7 known ✓ | P36544 | 1/20 | 0.33 |
| ▸ | MMP2 | P08253 | 1/20 | 0.36 |
| ▸ | ANPEP | P15144 | 1/20 | 0.36 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.33 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.33 |
| ▸ | ABAT | P80404 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL6081955 | 1.00 | MMP2 (0.36) | MMP2ANPEPCHRNB2CHRNA4ABAT | |
| Hydrochloric Acid SCHEMBL6079312 | 1.00 | MMP2 (0.36) | MMP2ANPEPCHRNB2CHRNA4ABAT | |
| Hydrochloric Acid SCHEMBL4093850 | 1.00 | MMP2 (0.36) | MMP2ANPEPCHRNB2CHRNA4ABAT | |
| SCHEMBL14480001 | 0.98 | MMP2 (0.37) | MMP2ANPEPCHRNB2CHRNA4ABAT | |
| SCHEMBL2208895 | 0.98 | MMP2 (0.37) | MMP2ANPEPCHRNB2CHRNA4ABAT | |
| SCHEMBL19337855 | 0.98 | MMP2 (0.37) | MMP2ANPEPCHRNB2CHRNA4ABAT | |
| SCHEMBL993865 | 0.98 | MMP2 (0.37) | MMP2ANPEPCHRNB2CHRNA4ABAT | |
| SCHEMBL993866 | 0.98 | MMP2 (0.37) | MMP2ANPEPCHRNB2CHRNA4ABAT | |
| Sulfuric Acid SCHEMBL6078885 | 0.91 | MMP2 (0.33) | MMP2ANPEPCHRNB2CHRNA4ABAT | |
| Sulfuric Acid SCHEMBL6078882 | 0.91 | MMP2 (0.33) | MMP2ANPEPCHRNB2CHRNA4ABAT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 54 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122079801-A | Synthesis method and analysis method of (1S, 4R) -4-amino-2-cyclopentene-1-carboxylic acid methyl ester tartrate | — | 2026-05-26 | — | — | CN | claimed |
| CN-122079801-A | Synthesis method and analysis method of (1S, 4R) -4-amino-2-cyclopentene-1-carboxylic acid methyl ester tartrate | — | 2026-05-26 | — | — | CN | disclosed |
| CN-122079801-A | Synthesis method and analysis method of (1S, 4R) -4-amino-2-cyclopentene-1-carboxylic acid methyl ester tartrate | — | 2026-05-26 | — | — | CN | disclosed |
| US-20260035335-A1 | PI3K-ALPHA INHIBITORS AND METHODS OF USE THEREOF | RELAY THERAPEUTICS INC (US) | 2026-02-05 | — | — | US | disclosed |
| US-12528822-B2 | Cycloalkane-1,3-diamine derivative | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2026-01-20 | — | — | US | disclosed |
| US-20260007131-A1 | HERBICIDAL COMPOSITION CONTAINING DIFLUOROBUTENOIC ACID AMIDE COMPOUND | ISHIHARA SANGYO KAISHA, LTD. (JP) | 2026-01-08 | — | — | US | disclosed |
| US-20250313524-A1 | PI3K-ALPHA INHIBITORS AND METHODS OF USE THEREOF | RELAY THERAPEUTICS, INC. | 2025-10-09 | — | — | US | disclosed |
| US-12319664-B2 | Herbicidally active 3-phenylisoxazoline-5-carboxamides of cyclopentenylcarboxylic acid derivatives | BAYER AKTIENGESELLSCHAFT (DE) | 2025-06-03 | — | — | US | disclosed |
| WO-2025111464-A1 | JAK2 V617F INHIBITORS AND METHODS OF USE THEREOF | RAYTHERA, INC. (US) | 2025-05-30 | — | — | WO | disclosed |
| WO-2025106788-A1 | PI3Kα INHIBITORS AND METHODS OF MAKING AND USING THE SAME | RELAY THERAPEUTICS, INC. (US) | 2025-05-22 | — | — | WO | disclosed |
| EP-1334969-A1 | PROCESS FOR PREPARATION OF 4-N-SUBSTITUTED AMINO-2-AZA-1-OXABICYCLO 3.3.0]OCT-2-ENE-6-CARBOXYLIC ACID ESTERS AND PROCESS FOR PREPARATION OF THEIR INTERMEDIATES | KURARAY CO., LTD. (JP) | 2003-08-13 | — | — | EP | disclosed |
| US-6562861-B1 | (1R,3R,4R,1'S)-(-)-(1'-acetylamino-2 '-ethyl)butyl-4-(aminoimino)methylaminocyclopentan-1-carboxylic acid was prepd. and tested in vitro as neuraminidase inhibitor (IC50 less-than 1.mu.M). Bactericides or viricides | BIOCRYST PHARMACEUTICALS, INC. | 2003-05-13 | — | — | US | disclosed |
| EP-0434450-B1 | Therapeutic nucleosides | WELLCOME FOUND (GB) | 1999-07-07 | — | — | EP | disclosed |
| EP-0921114-A1 | Intermediates to therapeutic nucleosides | THE WELLCOME FOUNDATION LIMITED (GB) | 1999-06-09 | — | — | EP | disclosed |
| EP-0921121-A1 | Intermediates to therapeutic nucleosides | THE WELLCOME FOUNDATION LIMITED (GB) | 1999-06-09 | — | — | EP | disclosed |
| US-5206435-A | Viricides; HIV, aides | BURROUGHS WELLCOME CO. (US) | 1993-04-27 | — | — | US | disclosed |
| US-5089500-A | Viricides; hepatitis, aids | BURROUGHS WELLCOME CO. (US) | 1992-02-18 | — | — | US | disclosed |
| US-5087697-A | Aids, viricides | BURROUGHS WELLCOME CO. (US) | 1992-02-11 | — | — | US | disclosed |
| US-5034394-A | Therapeutic nucleosides | BURROUGHS WELLCOME CO. (US) | 1991-07-23 | — | — | US | disclosed |
| EP-0434450-A2 | Therapeutic nucleosides | THE WELLCOME FOUNDATION LIMITED (GB) | 1991-06-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250313524-A1 | PI3K-ALPHA INHIBITORS AND METHODS OF USE THEREOF | PIK3CA, PIK3CB, PIK3CD | CHRNB4 3970/4885CHRNA3 3914/4885CHRNA7 4131/4885 |
| US-12319664-B2 | Herbicidally active 3-phenylisoxazoline-5-carboxamides of cyclopentenylcarboxylic acid derivatives | AADAC, PRDX5, DDT | CHRNB4 3822/4885CHRNA3 1742/4885CHRNA7 884/4885 |
| US-20260007131-A1 | HERBICIDAL COMPOSITION CONTAINING DIFLUOROBUTENOIC ACID AMIDE COMPOUND | DDT, CBR1, DHCR24 | CHRNB4 1962/4885CHRNA3 1067/4885CHRNA7 1266/4885 |
| US-20260035335-A1 | PI3K-ALPHA INHIBITORS AND METHODS OF USE THEREOF | PIK3CD, PIK3CG, PIK3CB | CHRNB4 2374/4885CHRNA3 2288/4885CHRNA7 3416/4885 |
| US-12528822-B2 | Cycloalkane-1,3-diamine derivative | MLLT1, MLLT3, PRMT6 | CHRNB4 2982/4885CHRNA3 2388/4885CHRNA7 2346/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.